Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO

publication date: Nov 30, 2021

Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. It is the third listing for the company, following NASDAQ and Hong Kong IPOs. The STAR Board shares, which represent 8.6% of BeiGene's total outstanding shares, are expected to begin trading on December 15. BeiGene develops medicines that are novel, affordable and improve treatment of serious diseases. Its portfolio includes more than 40 clinical candidates. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.